Boston Scientific just suffered a staggering 17% collapse, wiping out billions in market value in a single day. Despite beating earnings expectations and posting healthy revenue growth, the medical device giant hit a wall when it revealed a cooling outlook for 2026. Is the "perfection" priced into BSX finally evaporating?

In this episode of Implied, we dissect the "tantrum" on Wall Street. We dive into the surprising miss in their heart-procedure tech, the rising heat from rivals like Medtronic and J&J, and the eyebrow-raising timing of CEO share sales. Is this a dangerous reset for a company that flew too close to the sun, or a rare entry point into a double-digit grower? Tune in to find out if the "Farapulse" era of dominance is officially under threat.